Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease | Zendy

Surein Arulananda | Zendy; Hongdo Do | Zendy; Gareth Rivalland | Zendy; Zoe Loh | Zendy; Ashan Musafer | Zendy; Eddie Lau | Zendy; Paul Mitchell | Zendy; Alexander Dobrovic | Zendy; Thomas John | Zendy

Open Access

Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease

Author(s) -

Surein Arulananda,

Hongdo Do,

Gareth Rivalland,

Zoe Loh,

Ashan Musafer,

Eddie Lau,

Paul Mitchell,

Alexander Dobrovic,

Thomas John

Publication year - 2019

Publication title -

journal of thoracic disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 60

eISSN - 2077-6624

pISSN - 2072-1439

DOI - 10.21037/jtd.2019.05.41

Subject(s) - osimertinib , t790m , medicine , erlotinib , lung cancer , epidermal growth factor receptor , oncology , resistance mutation , pathology , cancer research , cancer , gefitinib , biology , reverse transcriptase , rna , biochemistry , gene

Leptomeningeal spread in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor ( EGFR ) mutations who experience disease progression on TKIs portends a poor prognosis. Mutation profiling of tumour DNA in cerebrospinal fluid (CSF) samples can be used to determine the presence of the EGFR T790M resistance mutation, indicating that osimertinib, a CNS-penetrating 3 rd generation TKI may be efficacious.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research